Alzheimer's Clinical Trials 2026: Lecanemab, Donanemab, and Disease-Modifying Treatments
3,865 alzheimer's disease trials indexed, 1,752 currently recruiting. Updated daily from ClinicalTrials.gov.
Understanding Alzheimer's Disease
Alzheimer's disease is a progressive brain disorder that slowly destroys memory and thinking skills. It is the most common cause of dementia, a group of brain disorders that impair daily functioning. The disease is marked by changes in the brain's structure, including the buildup of amyloid plaques and tau tangles. These abnormal protein deposits disrupt communication between nerve cells and eventually lead to their death. Doctors diagnose Alzheimer's through a combination of medical history, cognitive tests, brain imaging, and sometimes biomarkers found in blood or spinal fluid.
Symptoms usually begin with mild memory loss and confusion, gradually worsening over time. People may struggle with language, problem-solving, and recognizing familiar faces or places. While Alzheimer's can affect adults younger than 65, it typically starts after age 65. The risk increases with age, and women are affected more often than men. Other risk factors include a family history of the disease, certain genetic traits, cardiovascular conditions, and lifestyle factors such as smoking or lack of exercise.
Alzheimer's disease is a major public health concern worldwide. In the United States alone, over 6 million people live with the condition. It is the sixth leading cause of death, with nearly 1 in 3 seniors dying from Alzheimer's or other dementias. The economic impact is also significant, with estimated costs exceeding $350 billion annually in the U.S. alone. These figures highlight the urgent need for better treatments and support for patients and caregivers.
The Alzheimer's Disease Treatment Landscape
The first-line treatment for Alzheimer's disease often involves cholinesterase inhibitors, which aim to improve communication between nerve cells by increasing levels of a brain chemical called acetylcholine. Common drugs in this category include donepezil, rivastigmine, and galantamine. These medications may help with memory and thinking for some patients, especially in the early to moderate stages of the disease. Treatment usually starts with these drugs before considering additional options.
Second- and third-line treatments include memantine, which regulates glutamate activity to protect brain cells from damage. In recent years, new anti-amyloid antibodies such as aducanumab, lecanemab (marketed as Leqembi), and donanemab (Kisunla) have been approved. These drugs target amyloid plaques directly and are intended for early-stage Alzheimer's disease. Several Phase 3 trials are ongoing to confirm their benefits and explore different dosing methods, including subcutaneous injections and longer treatment durations. Other drug classes under study include BACE inhibitors, which aim to reduce amyloid production, though some have faced challenges in clinical development.
Current treatments have limitations. Many patients experience only modest improvements or no benefit at all. Side effects such as brain swelling or bleeding can occur with anti-amyloid antibodies. Some people do not tolerate existing drugs well, and there is no approved therapy that fully stops or reverses the disease. Research is now focusing on combination therapies, earlier intervention, and targeting tau protein, which forms tangles inside nerve cells. Additionally, lifestyle and exercise trials like FINGER and the U.S. POINTER study explore non-drug approaches to slow cognitive decline alongside medical treatments.
Why Clinical Trials Matter for Alzheimer's Disease
Clinical trials offer patients the chance to access new Alzheimer's treatments before they are widely available. Trials are essential for testing the safety and effectiveness of drugs like lecanemab and donanemab in different populations and stages of disease. Patients in trials receive close monitoring and contribute valuable data that help advance scientific knowledge. There are currently 3,865 Alzheimer's disease clinical trials indexed on ClinicalTrials.gov, with 1,752 actively recruiting participants. These studies cover a range of approaches, from anti-amyloid antibodies to tau-targeting therapies and lifestyle interventions.
Participating in a clinical trial also involves risks. The effectiveness of new treatments is not guaranteed, and some patients may receive a placebo instead of the active drug. Additional clinic visits, tests, and procedures can add time and effort. Side effects may occur, some of which might be unexpected. Patients and caregivers should carefully weigh the potential benefits and risks before enrolling in a trial and discuss these with their healthcare providers.
The Alzheimer's clinical trial landscape includes a mix of sponsors such as academic institutions, pharmaceutical companies, and cooperative research groups. ClinicalTrials.gov serves as a centralized registry where patients and caregivers can find information about ongoing studies. This transparency helps match volunteers with suitable trials and supports the overall effort to develop better treatments. As new options like Leqembi and Kisunla continue to be studied, clinical trials remain a vital part of improving care for people with Alzheimer's disease.
What to Look for in a Alzheimer's Disease Clinical Trial
Clinical trials are organized into four main phases that test the safety and effectiveness of new treatments. Phase 1 trials focus on safety and dosage with a small number of participants. Phase 2 trials look at effectiveness and side effects in a larger group. Phase 3 trials compare the new treatment to standard care in even more people. Phase 4 trials happen after a drug is approved to monitor long-term effects. For Alzheimer's disease, there are currently 201 trials with no phase specified, 136 in Phase 1, 116 in Phase 2, and 33 in Phase 3. This shows many early-stage studies and a growing number of confirmatory trials.
When joining an Alzheimer's clinical trial, participants usually need to meet specific criteria. Age is often a factor, with many trials focusing on people aged 50 to 85 years. Some trials require evidence of early-stage Alzheimer's or mild cognitive impairment through tests or brain scans. Biomarkers like amyloid or tau proteins may be needed to confirm diagnosis. Prior treatments might be restricted, especially if the trial tests new drugs like lecanemab or donanemab. The length of disease and severity also influence eligibility to ensure safety and clear results.
Exclusion criteria help protect participants and improve study quality. People with other serious health problems, such as heart disease or uncontrolled diabetes, are often excluded. This is because such conditions can affect safety or confuse results. Drug interactions are carefully considered, so participants cannot take certain medications that might interfere with the trial drug. Safety thresholds, like kidney or liver function levels, are used to avoid risks. These rules help researchers focus on the effects of the Alzheimer's treatment itself.
Practical considerations are important for anyone thinking about joining a trial. Trials can last from several months to a few years, with regular visits for tests and drug administration. Travel to the study site may be required, which can be challenging for some patients and caregivers. Before enrolling, patients should ask the research team about the expected schedule, possible side effects, what happens if they want to leave the study early, and how the trial drug compares to existing treatments. Understanding these details helps participants make informed decisions and plan for their involvement.
Primary Sources and Further Reading
For those interested in learning more about Alzheimer's disease clinical trials and new treatment options, several trusted sources provide detailed and up-to-date information. These resources cover everything from the basics of the disease to ongoing research efforts and approved therapies. Exploring these sites can help patients, caregivers, and healthcare providers stay informed about developments like the new Alzheimer treatment 2026 and the progress of lecanemab trials and donanemab trials.
- Alzheimer's Disease Fact Sheet - National Institute on Aging
- Alzheimer Clinical Trials - ClinicalTrials.gov
- Alzheimer's Disease Information - National Institute of Neurological Disorders and Stroke
- Alzheimer's Disease - MedlinePlus
Latest Research and Emerging Treatments for Alzheimer's Disease (2026)
Recent FDA approvals of lecanemab (Leqembi) and donanemab (Kisunla) introduced a new class of anti-amyloid antibodies for early-stage Alzheimer's disease. These drugs work by targeting amyloid plaques in the brain, which are thought to contribute to memory loss and cognitive decline. By helping to clear these plaques, the treatments aim to slow disease progression. Ongoing Phase 3 trials are exploring different ways to use these drugs, including subcutaneous injections and longer treatment durations, to improve convenience and effectiveness. These trials, such as those studying Leqembi and Kisunla, are key parts of the current alzheimer's disease research landscape.
Alongside anti-amyloid therapies, researchers are testing tau-targeting treatments that focus on another protein involved in Alzheimer's disease. Early data suggests these therapies may help reduce brain changes linked to worsening symptoms. Additionally, lifestyle and exercise studies like the FINGER and U.S. POINTER trials investigate how diet, physical activity, and social engagement might complement drug treatments. These approaches aim to support brain health and improve quality of life for people with Alzheimer's.
Other Phase 3 trials are exploring treatments for symptoms related to Alzheimer's. For example, KarXT is being tested for psychosis associated with Alzheimer's, which includes hallucinations and delusions (NCT06126224). If successful, this oral medication could offer new options for managing these challenging symptoms. While some trials focus on cancer therapies such as saruparib and immune checkpoint inhibitors, the Alzheimer's field remains focused on refining new drugs for alzheimer's disease and expanding treatment choices. Together, these efforts reflect a broad approach to improving care and outcomes for patients with Alzheimer's disease in 2026.
Frequently asked questions about Alzheimer's Disease trials
How do I find Alzheimer's Disease clinical trials?
The authoritative source for Alzheimer's Disease clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 3,865 alzheimer's disease studies are currently indexed. You can search by entering "alzheimer's disease" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new alzheimer's disease trials and delivers a plain-language briefing every Friday explaining what changed.
What phase are most Alzheimer's Disease trials in?
Across the 3,865 alzheimer's disease trials TrialsAlert indexes, the most common phase is Phase 1. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.
How many Alzheimer's Disease clinical trials are currently recruiting?
As of the latest scan, 1,752 alzheimer's disease trials have a "Recruiting" status on ClinicalTrials.gov, out of 3,865 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting alzheimer's disease trial matches their tracked condition.
Stay informed about alzheimer's disease research
Get a weekly briefing with the trials that matter most.